Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKIPP2: Cabozantinib Dose Skipping as an Alternative to Dose Reductions
2025-522962-58-00Phase 2Authorised
- Sponsor
- Leiden University Medical Center
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in renal cell carcinoma (RCC), sponsored by Leiden University Medical Center. Primary endpoints: Area under the concentration-time curve (AUC0-72) and Trough plasma concentration (Ctrough). Planned start Nov 2025; status: authorised.
02
Drugs
cabozantinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2025-522962-58-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522962-58-00.